These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 7329157

  • 1. The effect of neostigmine on pyridostigmine bioavailability in myasthenic patients after oral administration.
    Chan K, Davison SC, Dehghan A, Hyman N.
    Methods Find Exp Clin Pharmacol; 1981; 3(5):291-6. PubMed ID: 7329157
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Serum levels of pyridostigmine in myasthenia gravis: methods and clinical significance].
    Schumm F, Gaertner HJ, Wiatr G, Dichgans J.
    Fortschr Neurol Psychiatr; 1985 Jun; 53(6):201-11. PubMed ID: 2991094
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Steady state kinetics of pyridostigmine in myasthenia gravis.
    Sørensen PS, Flachs H, Friis ML, Hvidberg EF, Paulson OB.
    Neurology; 1984 Aug; 34(8):1020-4. PubMed ID: 6540381
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Continuous infusion of pyridostigmine for myasthenic crisis.
    Nicholson J, Grant IS.
    Crit Care Med; 1994 May; 22(5):895-6. PubMed ID: 8181302
    [No Abstract] [Full Text] [Related]

  • 11. Renal clearance of pyridostigmine in patients with myasthenia gravis.
    Chan K, Calvey TN.
    Eur Neurol; 1977 May; 16(1-6):69-72. PubMed ID: 615720
    [Abstract] [Full Text] [Related]

  • 12. Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis.
    Breyer-Pfaff U, Maier U, Brinkmann AM, Schumm F.
    Clin Pharmacol Ther; 1985 May; 37(5):495-501. PubMed ID: 3987173
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Use of pyridostigmine for the reversal of neuromuscular blockade.
    McNall PG, Wolfson B, Tuazon JG, Siker ES.
    Anesth Analg; 1969 May; 48(6):1026-32. PubMed ID: 5391379
    [No Abstract] [Full Text] [Related]

  • 15. [Electroacupuncture warming therapy combined with western medicine for treatment of myasthenia gravis and effect on IL-4 level in the patients].
    Wang SH, Cui X, Feng J.
    Zhongguo Zhen Jiu; 2007 Dec; 27(12):901-3. PubMed ID: 18271233
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The excretion and metabolism of oral 14C-pyridostigmine in the rat.
    Husain MA, Roberts JB, Thomas BH, Wilson A.
    Br J Pharmacol; 1968 Oct; 34(2):445-50. PubMed ID: 5687596
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cardiac dysrhythmia following reversal of neuromuscular blocking agents in geriatric patients.
    Owens WD, Waldbaum LS, Stephen CR.
    Anesth Analg; 1978 Oct; 57(2):186-90. PubMed ID: 565156
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.